Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
Dickran Kazandjian(United States Food and Drug Administration), Ola Landgren(University of Miami Health System), Elisabet E. Manasanch(National Institutes of Health), Ashley Carpenter(National Cancer Institute), Crystal Lu(National Institutes of Health Clinical Center), Seth M. Steinberg(National Institutes of Health), Mark Roschewski(National Cancer Institute), Katherine R. Calvo(National Institutes of Health Clinical Center), Manisha Bhutani(Carolinas Healthcare System), Mary Kwok(National Cancer Institute), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Neha Korde(United States Fish and Wildlife Service), Alexander Dew(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Esther Mena(National Institutes of Health), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Nisha Patel(National Institutes of Health), Peter L. Choyke(National Cancer Institute), Monica Epstein(Unknown), Nishant Tageja(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Yong Zhang(National Institutes of Health), Elizabeth Hill(University of Maryland, Baltimore), Irina Marić(Center for Cancer Research), Michael Emanuel(National Institutes of Health), Alina Dulau‐Florea(National Institutes of Health), Candis Morrison(National Institutes of Health), Constance M. Yuan(National Cancer Institute)
Cited by 10
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744